Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia
- 31 December 2010
- journal article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42 (12) , 902-907
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patientsJournal of Gastroenterology and Hepatology, 2009
- Antiviral resistance and hepatitis B therapy #Hepatology, 2009
- The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound†Hepatology, 2008
- Viral Persistence After Liver Transplantation for Hepatitis B Virus: A Cross-Sectional StudyTransplantation, 2008
- Hepatitis B virus escape mutants induced by antiviral therapyJournal of Antimicrobial Chemotherapy, 2008
- Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistanceHepatology, 2008
- Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD MotifAntimicrobial Agents and Chemotherapy, 2006
- Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine†Hepatology, 2005
- Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver diseaseHepatology, 2002
- Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis BHepatology, 2000